Articles related to CHECKPOINT INHIBITORS

This study demonstrates how pharmacists can improve patient safety and dramatically save costs in the management of chronic myeloid leukemia by highlighting the possibility of pharmacist-led TKI cessation programs.

A phase II trial showed a significant progression-free survival benefit when patients with HR+/HER2- metastatic breast cancer switched endocrine therapy and received ribociclib, indicating the potential of this treatment strategy for those who progress on endocrine therapy and palbociclib. Learn more about the findings and implications for clinical practice.

This article reviews the novel CXCR4 inhibitor motixafortide and its use in hematopoietic stem-cell mobilization. We present a history of stem-cell mobilization and update of recent innovations in novel mobilization strategies. Hematopoietic stem-cell mobilization is a crucial step in autologous stem-cell transplantation. Motixafortide is a novel CXCR4 inhibitor that has been shown in preclinical and clinical trials to mobilize hematopoietic stem cells (HSCs) for transplantation. The drug has extended in vivo activity (>48 h) and high affinity (Ki, 0.32 nM). In a phase 1, two-part study, motixafortide administered to healthy subjects was safe, well tolerated, and led to a rapid and robust increase in the number of circulating HSCs. Motixafortide has been evaluated in a randomized phase 3 trial for autologous transplantation in multiple myeloma. The study showed that the combination of motixafortide and granulocyte colony-stimulating factor (G-CSF) was superior to G-CSF alone in terms of the number of CD34+ cells collected and the time to engraftment. The drug has also been evaluated in combination with plerixafor, another CXCR4 inhibitor, in a phase 1/2 study for autologous transplantation in multiple myeloma. The study showed that the combination of motixafortide and plerixafor was safe and effective in mobilizing HSCs. Motixafortide has […]

In a recent study presented at the American Association for Thoracic Surgery (AATS) Annual Meeting, researchers reported that more than 75% of patients who received neoadjuvant chemotherapy combined with an immune checkpoint inhibitor (ICI) were still alive and event-free at 1 year. The treatment was also well-tolerated, with a manageable rate of side effects. The 1-year event-free survival rate was 78.3%, and the 1-year overall survival rate was 88.0%. The postoperative complication rate was 35.6%, and the rate of grade 3 or higher treatment-related adverse events was 18.1%. The most common side effects were leukopenia, neutropenia, thrombocytopenia, anemia, and hyperglycemia. Overall, the results of this study suggest that neoadjuvant chemotherapy combined with an ICI is a safe and effective treatment option for patients with resectable esophageal cancer. The treatment was associated with a high rate of pCR and R0 resection, and the side effects were generally manageable.

The number of patients who get immune-related adverse events (irAEs) will increase as the reasons for immune checkpoint inhibitors (ICI) therapy broaden. Because irAEs can progress and result in catastrophic or fatal results, early detection and therapy are crucial. Systemic corticosteroids and immunosuppressive medications are crucial to treating moderate to severe irAEs, although withdrawal of ICIs is often advised for high-grade occurrences. Preventing irAEs, treating corticosteroid-refractory instances, and evaluating whether ICIs may be safely reintroduced after the incidence of severe irAEs are all challenges. The ongoing search for predictive biomarkers of irAEs is critical for informing treatment strategies that maximize the clinical advantages of ICIs while lowering the risk of toxicities.

This educational program aims to improve the knowledge and comprehension of the clinical trial and real-world evidence for the CDK4/6i class among HCPs. A greater percentage of patients with HR+/HER2 metastatic breast cancer (mBC) will have access to this therapeutic option by filling care gaps linked to CDK4/6i usage. The course will largely center on three (3) core learning areas: best practices in CDK4/6i therapy management, the significance of real-world evidence (RWE) in treatment decision-making, and CDK4/6i in mBC: indications, clinical data, and RWE.